Rezultati
eNauka >
Rezultati >
Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG ph
Naziv: | Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG ph | Autori: | Petzer, Andreas L; Fong, Dominic; Lion, Thomas; Dyagil, Irina; Masliak, Zvenyslava; Bogdanovic, Andrija D ; Griskevicius, Laimonas; Lejniece, Sandra; Goranov, Stefan; Gercheva, Liana; | Godina: | 2011 | Publikacija: | ONKOLOGIE | ISSN: | 0378-584X Onkologie Pretraži identifikator | Tip rezultata: | Konferencijski rad | Kolacija: | vol. 34 str. 264-264 | WoS-ID: | 000295160600709 | URI: | https://enauka.gov.rs/handle/123456789/821878 | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | Mp kategorija će biti prikazana naknadno. |
Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.